Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2026
Reporting Period: Quarter and full year ended December 31, 2025
This filing serves as a notification of two primary events: the announcement of financial results for the period ended December 31, 2025, and a regulatory update regarding the investigational gene therapy AMT-130 for Huntington's disease.
Key Financial Metrics
The Form 8-K text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this filing.
Material Changes
No specific material changes in financial performance or operational status are quantified in the text of this filing. The document indicates that a corporate update was provided alongside the financial results, but the details of these changes are contained within the referenced Exhibit 99.1.
Guidance, Outlook, and Regulatory Updates
- Regulatory Update: The Company issued a press release (Exhibit 99.2) regarding a regulatory update on AMT-130, its investigational gene therapy for Huntington's disease.
- Financial Outlook: The filing references a corporate update provided in the financial results press release (Exhibit 99.1), but specific guidance or forward-looking statements are not detailed in the 8-K text itself.
- Legal Status: The information furnished under Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 for specific financial results (revenue, net loss, cash position) for the quarter and full year ended December 31, 2025.
- Review Exhibit 99.2 for details on the regulatory status and timeline of AMT-130 for Huntington's disease.
- Verify the Company's liquidity position and cash runway as disclosed in the referenced press release.
- Confirm any updated clinical trial milestones or regulatory submission dates mentioned in the corporate update.